Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:OHI
NYSE:OHIHealth Care REITs

Assessing Omega Healthcare Investors (OHI) Valuation After Mixed Near Term Performance And Long Term Gains

Recent performance snapshot for Omega Healthcare Investors Omega Healthcare Investors (OHI) has seen mixed share performance recently, with the stock up about 1.8% over the past day but down around 5% over the past week and 3% over the past month. Over longer periods, the stock shows a different pattern, with total return of about 26% over the past year and very large multiyear gains, including roughly 7x over three years and about 0.8x over five years. See our latest analysis for Omega...
NYSE:KEY
NYSE:KEYBanks

Has The Strong 1 Year Rally Left KeyCorp (KEY) Fully Priced Or Still Attractive?

Wondering if KeyCorp's share price still reflects good value after a strong run, or if most of the easy gains are behind it? This article walks through what the current valuation actually says. KeyCorp shares last closed at US$21.76, with the stock up 2.0% over the past week, slightly down 2.1% over the past month, up 3.7% year to date, and up 38.9% over the past year, while the 3 year and 5 year returns stand at 137.8% and 26.4% respectively. Recent price moves sit against a backdrop of...
NYSE:ADCT
NYSE:ADCTBiotechs

Assessing ADC Therapeutics (ADCT) Valuation After Pivotal LOTIS-5 Phase 3 ZYNLONTA Trial Results

ADC Therapeutics (ADCT) has drawn fresh attention after reporting statistically significant Phase 3 LOTIS-5 topline data for ZYNLONTA plus rituximab in relapsed or refractory diffuse large B cell lymphoma, including improved progression free survival versus standard therapy. See our latest analysis for ADC Therapeutics. Despite the encouraging LOTIS-5 data, the stock’s 1-day share price return fell 21.97%, extending a 7-day share price decline of 69.71% and a 1-year total shareholder return...
NasdaqGS:SNPS
NasdaqGS:SNPSSoftware

Is Synopsys (SNPS) Still Fairly Priced After Recent Share Price Weakness?

If you are wondering whether Synopsys at around US$464.85 is priced for opportunity or already reflects high expectations, the key is to understand what different valuation tools actually say about the stock. Over shorter periods the picture has been mixed, with the share price down about 2.3% over the last week, down 7.8% over the last month, down 3.2% year to date, and down 4.4% over the last year. The 3 year and 5 year returns sit at 5.9% and 76.7% respectively. Recent coverage of...
NasdaqGM:KEEL
NasdaqGM:KEELSoftware

Keel Infrastructure Upsized US$400 Million Notes Test AI Growth Plan

Keel Infrastructure (NasdaqGM:KEEL) has completed an upsized US$400 million convertible senior notes offering, above the initial US$350 million target. The transaction is intended to fund capped call arrangements and support expansion of data center projects for AI and high performance computing workloads. The offering adds financial flexibility as Keel continues its shift from Bitcoin mining toward broader digital infrastructure. Keel is positioning itself as a digital infrastructure...
NYSE:BIPC
NYSE:BIPCGas Utilities

Is Brookfield Infrastructure (BIPC) Pricing In Too Much Growth After Recent Share Price Rebound

For investors wondering whether Brookfield Infrastructure at around US$41.31 offers value or is asking too much for its future, this breakdown is designed to help frame that question in a clear, practical way. The stock has been slightly softer over the last week, with a 0.5% decline, but has gained 4.6% over the past month. Year to date it is down 8.8% and it is up 5.7% over the last year, with a 2.1% decline over three years and a 7.3% gain over five years. Recent price moves sit against a...
NasdaqGM:AUPH
NasdaqGM:AUPHBiotechs

Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook

Aurinia Pharmaceuticals (NasdaqGM:AUPH) reported new AURORA 1 Phase 3 data at EULAR 2026 showing LUPKYNIS reduced the risk of renal events or death in lupus nephritis. The findings were presented at a major international rheumatology congress, putting fresh clinical evidence for LUPKYNIS in front of global specialists. Tang Capital Management increased its stake in Aurinia, and senior company executives acquired additional shares. Aurinia focuses on therapies for autoimmune kidney disease,...
TSE:5591
TSE:5591Software

If AI Small Caps Keep Surging These Three Stocks Could Matter

AI is no longer just a big tech story. With credit demand still holding up, global bond markets reacting to interest rate expectations, and employment data pointing to ongoing economic activity, investors are looking for focused ways to gain exposure to AI without relying only on giants. The AI Small Caps screener targets smaller companies working in areas like machine learning, automation, and data intelligence, where early-stage progress can meaningfully change the long term story. In this...
TSE:8591
TSE:8591Diversified Financial

Is It Too Late To Consider ORIX (TSE:8591) After Its 107% One-Year Surge?

If you are wondering whether ORIX at ¥6,113 still offers value after a strong run, this article walks through what the current price might be implying. The stock has been volatile in recent periods, with a decline of 2.0% over the last week, a 16.4% gain over the last 30 days, a 32.4% gain year to date, and a 107.1% gain over the last year, while the 3 year and 5 year returns are very large. Recent coverage has highlighted ORIX in the context of broader interest in Japanese financial stocks,...
NasdaqGS:MIDD
NasdaqGS:MIDDMachinery

Is It Time To Revisit Middleby (MIDD) After Its Recent Share Price Rebound?

Investors may be wondering if Middleby stock at around US$154.93 offers good value today, or if they are paying up mainly for the story. Over the past month the share price has risen 8.7%, while the 1-year return sits at 5.2% and the 5-year return shows a decline of 8.6%. This may hint at shifting views on both its potential and its risks. Recent coverage of Middleby has focused on its position in the capital goods space and investor interest in how its business model compares with peers...
TSE:2726
TSE:2726Specialty Retail

3 High Quality Undiscovered Gems With Striking ROE And Discounts

With inflation, interest rates and bond yields all pulling investors in different directions, it can feel hard to know where to look next. One area that often gets less attention is smaller high quality companies that are not yet crowded with big institutional money. That is exactly what the High-Quality Undiscovered Gems screener aims to highlight. It focuses on strong fundamentals in a world of mixed growth signals and patchy sentiment. In this article, you will see 3 stocks from this...
NYSE:IDA
NYSE:IDAElectric Utilities

Is It Too Late To Consider IDACORP (IDA) After A 26% One-Year Rally?

Investors may be wondering whether IDACORP at about US$141 per share is offering good value right now, or if the easy money has already been made. The stock is up 11.0% year to date and 26.0% over the past year, although it has slipped 1.9% over the last month and inched 0.8% higher over the last week. Recent coverage has focused on IDACORP as an established electric utility, with investors weighing regulated earnings, capital needs and its role in regional power infrastructure. That...
TSX:WPM
TSX:WPMMetals and Mining

Wheaton Precious Metals Cleantech Challenge Underscores Long Term Investment Case

Wheaton Precious Metals launched its third annual Future of Mining Challenge, offering a $1 million prize pool. The program focuses on cleantech solutions that can reduce the environmental impact of mining. The challenge invites global participants to propose technologies that can be applied across mining operations. For investors watching Wheaton Precious Metals (TSX:WPM), this initiative sits alongside a share price of about CA$161.89 and a long track record of positive multi year...
TSE:7279
TSE:7279Auto Components

Hi‑Lex (TSE:7279) One Off Gain Driven EPS Surge Challenges Bullish Narratives

Hi-Lex (TSE:7279) opened its Q2 2026 scorecard with revenue of ¥103.5b and basic EPS of ¥40.63, alongside trailing twelve month EPS of ¥1,116.54 that is heavily influenced by a ¥40.0b one off gain and a trailing net margin of 11.5% compared with 1.2% a year earlier. The company has seen revenue move from ¥74.8b in Q2 2025 to ¥103.5b in Q2 2026 and quarterly basic EPS shift from ¥27.40 to ¥40.63 over the same period. Trailing twelve month EPS has risen from ¥59.44 in Q1 2025 to ¥1,116.54 in Q2...
NYSE:NOV
NYSE:NOVEnergy Services

Is It Too Late To Consider NOV (NOV) After Its 63.7% One Year Surge?

If you are wondering whether NOV at around US$20.14 still offers value or if most of the opportunity is already priced in, you are asking the right question. The stock has returned 0.9% over the past week, is roughly flat over the last month with a 0.2% decline, and sits on a 22.7% year to date gain and 63.7% return over the past year. This naturally raises questions about how much upside or risk is now on the table. Recent coverage of NOV has focused on its role in the energy equipment and...
NYSE:COUR
NYSE:COURConsumer Services

Coursera (COUR) Valuation Check As Employer Demand For Micro Credentials Strengthens

Coursera (COUR) released a new report indicating that 92% of US employers are willing to offer higher starting salaries to graduates with industry micro-credentials, putting the stock’s online upskilling focus back in the spotlight. See our latest analysis for Coursera. The latest employer survey lands against a tougher backdrop for shareholders, with Coursera’s share price down 22.74% year to date and the 1 year total shareholder return down 38.75%, suggesting weak recent momentum despite...
CPSE:ALK B
CPSE:ALK BPharmaceuticals

Assessing ALK-Abelló (CPSE:ALK B) Valuation As New Allergy Data Takes Center Stage

Conference spotlight and scientific data in focus ALK-Abelló (CPSE:ALK B) is back in the spotlight as it prepares to share extensive real world and long term data on its allergy treatments at the EAACI congress and the Jefferies Global Healthcare Conference. For you as an investor, these events matter because they put the company’s allergy immunotherapy portfolio, including sublingual immunotherapy tablets and nasal adrenaline for anaphylaxis, in front of clinicians and healthcare specialists...
ASX:RSG
ASX:RSGMetals and Mining

A Look At Resolute Mining’s (ASX:RSG) Valuation After Syama Operational Challenges And Updated Guidance

Resolute Mining (ASX:RSG) has updated the market after operational challenges at its Syama Gold Mine in Mali, where security related logistical issues have disrupted second quarter 2026 production and prompted revised expectations. See our latest analysis for Resolute Mining. The share price has come under short term pressure, with 1 day, 7 day and 30 day share price returns down 5.02%, 11.67% and 13.36% respectively. However, the 1 year total shareholder return of 95.69% and 3 year total...
XTRA:DHL
XTRA:DHLLogistics

DHL Fuel Security Supports Deutsche Post Valuation Debate And Recent Momentum

DHL Express has confirmed secure jet fuel supplies for its European air network, addressing concerns about potential fuel shortages. The company highlights contingency planning and a flexible aviation setup to support uninterrupted delivery services. This update targets customers and investors focused on service continuity and operational resilience. For Deutsche Post (XTRA:DHL), this fuel update comes with the stock trading at €52.16 and showing solid recent momentum, up 11.4% over the...
ENXTPA:BNP
ENXTPA:BNPBanks

Is BNP Paribas (ENXTPA:BNP) Still Attractive After Strong Multi‑Year Share Price Gains?

Wondering if BNP Paribas at €93.65 is still offering value or if most of the easy gains are already behind it? This article walks through the numbers so you can judge for yourself. The stock has returned 0.8% over the last week, 0.3% over the last month, 14.3% year to date and 27.6% over the past year, with longer term returns of 102.0% over three years and 137.4% over five years putting recent moves into context. Recent coverage of BNP Paribas in broader market commentary has focused on how...
XTRA:P911
XTRA:P911Auto

Is It Too Late To Consider Porsche (XTRA:P911) After Recent Share Price Rebound?

Investors may be wondering whether Dr. Ing. h.c. F. Porsche stock still offers value at around €46.86, or if the market has already priced in the key stories around it. Over the past year the share price is up 13.6%. It is down 1.6% year to date and has fallen 56.0% over three years, so recent strength sits against a much weaker longer term record. Recent headlines around Dr. Ing. h.c. F. Porsche have focused on its position within the wider auto sector and how investors are weighing its...
ENXTPA:TTE
ENXTPA:TTEOil and Gas

TotalEnergies Russian LNG Exit And US Wind Dispute Reshape Growth Options

TotalEnergies (ENXTPA:TTE) has received Russian approval to exit the U.S. sanctioned Arctic LNG 2 project, unwinding its 10% stake. Seven U.S. states have launched legal action over a Trump era agreement tied to the company’s withdrawal from new offshore wind projects in the U.S. Both developments center on long term energy policy, sanctions, and the balance between fossil fuels and renewables in TotalEnergies’ portfolio. TotalEnergies is a large integrated energy company with oil, gas, and...
NasdaqCM:CHRN
NasdaqCM:CHRNIT

ChronoScale Hires AI Leaders As Investors Weigh Growth Versus Valuation Risks

ChronoScale (NasdaqCM:CHRN) has expanded its executive team with senior hires from leading AI and technology firms. Raj Jegannathan, formerly a Vice President responsible for AI infrastructure at Tesla, has joined ChronoScale. Lawrence Lam, a veteran in global cloud and AI platforms, has also been appointed to a leadership role. The company states that these appointments are intended to accelerate the expansion of its AI infrastructure platform. For investors tracking AI infrastructure,...